14 DUAL ORAL THERAPY WITH THE NS5A INHIBITOR DACLATASVIR...

14 DUAL ORAL THERAPY WITH THE NS5A INHIBITOR DACLATASVIR (BMS-790052) AND NS3 PROTEASE INHIBITOR ASUNAPREVIR (BMS-650032) IN HCV GENOTYPE 1B-INFECTED NULL RESPONDERS OR INELIGIBLE/INTOLERANT TO PEGINTERFERON/RIBAVIRIN

F. Suzuki, K. Ikeda, J. Toyota, Y. Karino, T. Ohmura, K. Chayama, S. Takahashi, Y. Kawakami, H. Ishikawa, H. Watanabe, W. Hu, F. McPhee, E. Hughes, H. Kumada
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
56
Year:
2012
Language:
english
DOI:
10.1016/s0168-8278(12)60028-2
File:
PDF, 117 KB
english, 2012
Conversion to is in progress
Conversion to is failed